The longer the antithyroid drug is used, the lower the relapse rate in Graves' disease: a retrospective multicenter cohort study in Korea
- Document Type
- Publications · Journal Article
- Registered DB
- SCIEScopus
- Journal Ranking
- JCR Q3Scopus Q2
- Journal
- ENDOCRINE74(1) · pp.120 · 2021
- Citation
- Web of Science 30Scopus 33
- FWCI (Scopus)
- 1.61
- JCR IF
- JCR 2020 3.633
- ISSN
- 1355-008X
Authors
- Park, So YoungFirst authorDivision of Endocrinology and Metabolism, Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- Kim, Byounghan HyunDivision of Endocrinology and Metabolism, Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Busan, Korea
- Kim, MijinDivision of Endocrinology and Metabolism, Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Busan, Korea
- Hong, A.RamDepartment of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea
- Park, JunDivision of Endocrinology and Metabolism, Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- Park, HyunjuDivision of Endocrinology and Metabolism, Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- Choi, Min SunDivision of Endocrinology and Metabolism, Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- Kim, Tae HyukDivision of Endocrinology and Metabolism, Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- Kim, Sun WookDivision of Endocrinology and Metabolism, Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- Kang, Ho-CheolCorresponding authorDepartment of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea
- Chung, Jae HoonCorresponding authorDivision of Endocrinology and Metabolism, Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Abstract
Purpose Current literature suggests 12-18 months of antithyroid drug (ATD) treatment for patients with Graves' disease, but the risk of relapse is high. Although some studies reported better outcomes of long-term ATD treatment, recent data that suggest the optimal treatment duration are limited. Methods We performed a multicenter retrospective cohort study of 908 patients newly diagnosed with Graves' disease between 2006 and 2013. The relapse rate according to ATD treatment duration was analyzed. Results After initial ATD treatment, 338 patients (37.2%) had relapsed. The relapse rate according to ATD treatment duration was 42.4% at 1 year, 38.5% at 2 years, 33.8% at 3 years, 31.7% at 4 years, 30.2% at 5 years, 27.8% at 6 years, and 19.1% at more than 6 years, respectively, demonstrating a significant decreasing trend (p = 0.003). In a multivariable Cox regression analysis, ATD treatment duration was an independent risk factor for relapse (p = 0.043). Conclusions The longer that ATD therapy is used, the lower the relapse rate is in patients with Graves' disease. Long-term ATD treatment may be considered in Graves' patients who do not show complications or an economic burden from hyperthyroidism.
Keywords
Grave’s diseaseHyperthyroidismAntithyroid agentsTreatment outcomeRecurrence
Identifiers
- Scopus EID
- 2-s2.0-85104722177
- WoS UID
- 000640443500001



Login
Back to Publication list